Mutant p53R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells

被引:132
作者
Kogan-Sakin, I. [1 ]
Tabach, Y. [2 ]
Buganim, Y. [1 ]
Molchadsky, A. [1 ]
Solomon, H. [1 ]
Madar, S. [1 ]
Kamer, I. [1 ]
Stambolsky, P. [1 ]
Shelly, A. [1 ]
Goldfinger, N. [1 ]
Valsesia-Wittmann, S. [3 ]
Puisieux, A. [3 ]
Zundelevich, A. [4 ]
Gal-Yam, E. N. [4 ]
Avivi, C. [5 ]
Barshack, I. [5 ]
Brait, M. [6 ]
Sidransky, D. [6 ]
Domany, E. [2 ]
Rotter, V. [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[2] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel
[3] INSERM, U590, F-69008 Lyon, France
[4] Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel
[5] Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel
[6] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA
关键词
p53; Twist1; prostate; P53; TUMOR-SUPPRESSOR; GAIN-OF-FUNCTION; CANCER; GENE; PROTEIN; MORPHOGENESIS; MUTATIONS; APOPTOSIS; CULTURES; MODEL;
D O I
10.1038/cdd.2010.94
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A mutation within one allele of the p53 tumor suppressor gene can inactivate the remaining wild-type allele in a dominant-negative manner and in some cases can exert an additional oncogenic activity, known as mutant p53 'gain of function' (GOF). To study the role of p53 mutations in prostate cancer and to discriminate between the dominant-negative effect and the GOF activity of mutant p53, we measured, using microarrays, the expression profiles of three immortalized prostate epithelial cultures expressing wild-type, inactivated p53 or mutated p53. Analysis of these gene expression profiles showed that both inactivated p53 and p53(R175H) mutant expression resulted in the upregulation of cell cycle progression genes. A second group, which was upregulated exclusively by mutant p53(R175H), was predominantly enriched in developmental genes. This group of genes included the Twist1, a regulator of metastasis and epithelial-mesenchymal transition (EMT). Twist1 levels were also elevated in metastatic prostate cancer-derived cell line DU145, in immortalized lung fibroblasts and in a subset of lung cancer samples, all in a mutant p53-dependent manner. p53(R175H) mutant bearing immortalized epithelial cells showed typical features of EMT, such as higher expression of mesenchymal markers, lower expression of epithelial markers and enhanced invasive properties in vitro. The mechanism by which p53(R175H) mutant induces Twist1 expression involves alleviation of the epigenetic repression. Our data suggest that Twist1 expression might be upregulated following p53 mutation in cancer cells. Cell Death and Differentiation (2011) 18, 271-281; doi: 10.1038/cdd.2010.94; published online 6 August 2010
引用
收藏
页码:271 / 281
页数:11
相关论文
共 28 条
[11]   Phenotypic plasticity and the epigenetics of human disease [J].
Feinberg, Andrew P. .
NATURE, 2007, 447 (7143) :433-440
[12]   Control of apoptosis by p53 [J].
Fridman, JS ;
Lowe, SW .
ONCOGENE, 2003, 22 (56) :9030-9040
[13]   A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain [J].
Gaiddon, C ;
Lokshin, M ;
Ahn, J ;
Zhang, T ;
Prives, C .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) :1874-1887
[14]   The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker? [J].
Heidenberg, HB ;
Bauer, JJ ;
McLeod, DG ;
Moul, JW ;
Srivastava, S .
UROLOGY, 1996, 48 (06) :971-979
[15]   hTERT-immortalized prostate epithelial and stromal-derived cells:: an authentic in vitro model for differentiation and carcinogenesis [J].
Kogan, I ;
Goldfinger, N ;
Milyavsky, M ;
Cohen, M ;
Shats, I ;
Dobler, G ;
Klocker, H ;
Wasylyk, B ;
Voller, M ;
Aalders, T ;
Schalken, JA ;
Oren, M ;
Rotter, V .
CANCER RESEARCH, 2006, 66 (07) :3531-3540
[16]   Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target [J].
Kwok, WK ;
Ling, MT ;
Lee, TW ;
Lau, TCM ;
Zhou, C ;
Zhang, XM ;
Chua, CW ;
Chan, KW ;
Chan, FL ;
Glackin, C ;
Wong, YC ;
Wang, XH .
CANCER RESEARCH, 2005, 65 (12) :5153-5162
[17]   Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome [J].
Lang, GA ;
Iwakuma, T ;
Suh, YA ;
Liu, G ;
Rao, VA ;
Parant, JM ;
Valentin-Vega, YA ;
Terzian, T ;
Caldwell, LC ;
Strong, LC ;
El-Naggar, AK ;
Lozano, G .
CELL, 2004, 119 (06) :861-872
[18]  
Milyavsky M, 2003, CANCER RES, V63, P7147
[19]   EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer [J].
Pietersen, Alexandra M. ;
Horlings, Hugo M. ;
Hauptmann, Michael ;
Langerod, Anita ;
Ajouaou, Abderrahim ;
Cornelissen-Steijger, Paulien ;
Wessels, Lodewijk F. ;
Jonkers, Jos ;
van de Vijver, Marc J. ;
van Lohuizen, Maarten .
BREAST CANCER RESEARCH, 2008, 10 (06)
[20]   Complex functions of mutant p53 alleles from human prostate cancer [J].
Shi, XB ;
Nesslinger, NJ ;
Deitch, AD ;
Gumerlock, PH ;
White, RWD .
PROSTATE, 2002, 51 (01) :59-72